ABOUT US

Company Profile

Proacta Inc., headquartered in San Diego, California, is a clinical-stage biopharmaceutical company working to develop hypoxia-activated prodrugs for the treatment of cancer.

Proacta was founded on intellectual property derived from research conducted in New Zealand at the University of Auckland and in the United States at Stanford University.

Proacta's patent family covers a series of hypoxia-activated prodrugs designed to treat cancer. Expansion of this portfolio is supported by ongoing research led by acknowledged international experts in the field at The University of Auckland and Stanford University.

Proacta is focused on addressing large unmet needs in the treatment of cancer.

To date, Proacta has raised $43 million in two private financings. Investors include Alta Partners, Clarus Ventures, Delphi Ventures, Endeavour Capital (New Zealand), GBS Venture Partners (Australia), Genentech, No 8 Ventures (New Zealand) and Roche.

In June 2004, Proacta Inc. acquired Proacta Therapeutics Limited (PTL). PTL was established by the University of Auckland, and in now a wholly-owned subsidiary of Proacta Inc.